Novo Nordisk and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101
Copenhagen, Denmark | October 06, 2008 | Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront payment, milestone payments and royalties on future sales of IPH 2101. In addition, Novo Nordisk receives fully paid-up exclusive rights to NN8555/IPH 2301.
NN1975/IPH 2101 is a monoclonal antibody targeting inhibitory receptors (KIR) on natural killer cells, with a novel mechanism of action; it is currently in two phase 1 clinical trials in haematological cancers
NN8555/IPH 2301 is a monoclonal antibody targeting natural killer cells and certain T cells, with a novel mechanism of action; it is currently in preclinical research within the area of inflammation.
The agreement is in line with Novo Nordisk’s decision to exit the oncology area and increase its activities within inflammation as communicated in the company’s Financial Statement for 2007, issued on 31 January 2008.
Novo Nordisk remains the single largest shareholder of Innate Pharma.
SOURCE: Novo Nordisk
Post Views: 71
Novo Nordisk and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101
Copenhagen, Denmark | October 06, 2008 | Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront payment, milestone payments and royalties on future sales of IPH 2101. In addition, Novo Nordisk receives fully paid-up exclusive rights to NN8555/IPH 2301.
NN1975/IPH 2101 is a monoclonal antibody targeting inhibitory receptors (KIR) on natural killer cells, with a novel mechanism of action; it is currently in two phase 1 clinical trials in haematological cancers
NN8555/IPH 2301 is a monoclonal antibody targeting natural killer cells and certain T cells, with a novel mechanism of action; it is currently in preclinical research within the area of inflammation.
The agreement is in line with Novo Nordisk’s decision to exit the oncology area and increase its activities within inflammation as communicated in the company’s Financial Statement for 2007, issued on 31 January 2008.
Novo Nordisk remains the single largest shareholder of Innate Pharma.
SOURCE: Novo Nordisk
Post Views: 71
